Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Trevena's Play Out Of Pain Space Fails In Phase IIb

Executive Summary

Trevena Inc.'s future as more than just a one-trick pony is in question following the company's announcement it is discontinuing development of acute heart failure therapy, TRV027, after the drug failed to meet primary or secondary endpoints in a Phase IIb study.


Related Content

Stockwatch: Fireworks Or Ballistic Missiles In Biotechnology?


Related Companies